[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368035-105":59,"doc-detail-368035-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","lem4-interacts-with-catenin-and-promotes-catenin-dependent-transcription-activity-to-confer-ribociclib-resistance-in-breast-cancer-cells","LEM4 interacts with β-catenin and promotes β-catenin-dependent transcription activity to confer ribociclib resistance in breast cancer cells","","Ribociclib is a CDK4/6-targeted therapy for breast cancer, but acquired resistance limits durable benefit. This study evaluates LEM4, a nuclear envelope protein, as a mediator of ribociclib resistance and clarifies the molecular mechanism. LEM4 expression is assessed in patient samples and cell lines; ribociclib-resistant MCF-7 and T47D models are generated. LEM4 knockdown is tested for effects on drug sensitivity, apoptosis, β-catenin signaling, and tumor formation. LEM4 overexpression associates with poorer survival, drives β-catenin stabilization and nuclear transcriptional activity, and its silencing re-sensitizes resistant cells to ribociclib in vitro and in vivo. β-catenin signaling inhibition reverses resistance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/lem4-interacts-with-catenin-and-promotes-catenin-dependent-transcription-activity-to-confer-ribociclib-resistance-in-breast-cancer-cells/368035/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/lem4-interacts-with-catenin-and-promotes-catenin-dependent-transcription-activity-to-confer-ribociclib-resistance-in-breast-cancer-cells/368035.png","ImageObject",300,407,{"name":92,"@type":93},"LangkahRina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-20","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the study?","Question",{"text":112,"@type":113},"To determine whether LEM4 mediates ribociclib resistance in breast cancer cells and to define the underlying molecular mechanism.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is ribociclib resistance modeled in this research?",{"text":117,"@type":113},"Ribociclib-resistant MCF-7 and T47D cell lines are established, and the impact of LEM4 knockdown is evaluated.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism connects LEM4 to ribociclib resistance?",{"text":121,"@type":113},"LEM4 interacts with β-catenin, enhancing β-catenin stability, nuclear translocation, and transcriptional activity; blocking β-catenin signaling reverses resistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368035,1790196863,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090893776,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nLEM4 interacts with β-catenin and promotes β-catenin-dependent transcription activity to confers ribociclib resistance in breast cancer cells  \nQi Tang􀀍, Xintong Zhao, Hui Li, Jiaqian Liao, Bingyu Ouyang, Chunxiao Ma & DedianChen􀀍 Background Ribociclib, a CDK4/6 inhibitor, is a targeted therapy for breast cancer management.  \nHowever, acquired resistance to ribociclib is a common clinical challenge. This study aimed to investigate the role of LEM-Domain Protein 4 (LEM4), a nuclear envelope protein, in mediating ribociclib resistance in breast cancer cells and elucidate the underlying molecular mechanisms. Methods LEM4 expression was analyzed in breast cancer patient samples and cell lines. Ribociclibresistant MCF-7 and T47D cell lines were established, and the effects of LEM4 knockdown on  \ndrug sensitivity, apoptosis, and β-catenin signaling were evaluated using in vitro cytotoxicity, coimmunoprecipitation, β-catenin transcription activity and in vivo tumor formation assays. Results LEM4 was found to be overexpressed in breast cancer tissues and cell lines, and its high expression correlated with worse overall survival in patients. Ribociclib-resistant breast cancer cells demonstrated significantly elevated LEM4 expression levels, and LEM4 silencing re-sensitized drug-resistant cells to ribociclib-induced cytotoxicity and apoptosis in vitro and in vivo. Mechanistically, LEM4 interacted with β-catenin, increasing its protein stability, nuclear translocation, and transcriptional activity. Inhibition of β-catenin signaling reversed ribociclib resistance. Conclusion This study identifies LEM4 asa key mediator of ribociclib resistance in breast cancer cells through its interaction with β-catenin and subsequent activation of β-catenin signaling. Targeting the LEM4/β-catenin axis represents a potential therapeutic strategy to overcome ribociclib resistance in breast cancer.  \nKeywords LEM4, Ribociclib resistance, Breast cancer, Β-catenin, Targeted therapy  \nBreast cancer represents the most prevalent malignancy and a leading cause of cancer-related mortality among women worldwide1. According to global cancer statistics, breast cancer accounted for approximately 2.3 million new cases and 666,000 deaths in 20221. While early-stage breast cancer is often treatable, metastatic or advanced disease remains a significant therapeutic challenge. Breast cancer is a heterogeneous disease with distinct molecular subtypes, including hormone receptor-positive, human epidermal growth factor receptor 2 (HER2) -positive, and triple-negative breast cancer, each requiring tailored treatment approaches2.  \nHormone receptor-positive breast cancers, which express estrogen receptor (ER) and/or progesterone receptor (PR), are typically treated with endocrine therapies, such as selective estrogen receptor modulators (e.g., tamoxifen) or aromatase inhibitors (e.g., letrozole, anastrozole)3. HER2-positive breast cancers, characterized by the overexpression of the HER2 protein, are treated with HER2-targeted therapies, including monoclonal antibodies (e.g., trastuzumab, pertuzumab) and small molecule inhibitors (e.g., lapatinib)4. Triple-negative breast cancers, lacking expression of ER, PR, and HER2, present as more aggressive subtypes with limited targeted therapy options, often necessitating cytotoxic chemotherapy as the primary treatment modality5. Despite these tailored treatment strategies, a significant proportion of patients develop resistance to therapy, leading to disease progression and poor outcomes, highlighting the need for novel therapeutic approaches6,7.  \nCyclin-dependent kinase (CDK) 4/6 inhibitors represent a significant advancement in the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer8. These targeted therapies  \nDepartment of Breast Surgery, Yunnan Cancer Hospital, The Third affiliated Hospital of Kunmming Medical Uni","cbCaivdfUANbHPVa","https://ap.wps.com/l/cbCaivdfUANbHPVa","pdf",7810823,14,"English","# Background\n## Clinical challenge of ribociclib resistance\n## Breast cancer heterogeneity and targeted options\n# Methods\n## LEM4 expression assessment\n## Ribociclib-resistant cell line establishment\n## Functional assays for drug response and signaling\n# Results\n## LEM4 overexpression and prognostic relevance\n## LEM4 silencing re-sensitizes cells\n## LEM4–β-catenin mechanistic pathway\n# Conclusion\n## Therapeutic potential of targeting the LEM4/β-catenin axis","[{\"question\":\"What is the main goal of the study?\",\"answer\":\"To determine whether LEM4 mediates ribociclib resistance in breast cancer cells and to define the underlying molecular mechanism.\"},{\"question\":\"How is ribociclib resistance modeled in this research?\",\"answer\":\"Ribociclib-resistant MCF-7 and T47D cell lines are established, and the impact of LEM4 knockdown is evaluated.\"},{\"question\":\"What mechanism connects LEM4 to ribociclib resistance?\",\"answer\":\"LEM4 interacts with β-catenin, enhancing β-catenin stability, nuclear translocation, and transcriptional activity; blocking β-catenin signaling reverses resistance.\"}]","LEM4 interacts with β-catenin and promotes β-catenin-dependent transcription activity to confer ribociclib resistance in breast cancer cells | PDF",1790174532,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b3b41ee4ea01deca3fab58e5b75227a9.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85c7ef58affc587bf8c19bcfea2a978f.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2f04987fa0f0d5bda99b04e71dfdfbf.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0fd9b872f300d9da77abb92e476fe6fa.webp",980,1287]